Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikolas Adamowitsch has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Preoperative Intravenous Crystalloid Bolus on Postinduction Blood Pressure: A Randomized Blinded Intervention Trial

    by Michael Eichinger, Christian Reiterer, Michael Eichlseder, Alexander Pichler, Alexander Taschner, Katharina Horvath, Hani Essber, Daniel Freidorfer, Nikolas Adamowitsch, Nicole Hantakova, et al.

    Background: Postinduction hypotension in major noncardiac surgery is common and a modifiable risk factor for adverse outcomes. There is an ongoing debate whether preoperative crystalloid fluid administration can reduce the incidence or severity of postinduction hypotension. This study aims to assess whether a preoperative intravenous crystalloid bolus reduces postinduction hypotension in high-risk patients during general anesthesia. Methods: This was a prospective, randomized, single-blind clinical trial conducted at two centers in Austria (Medical University of Graz, Medical University of Vienna). Adult patients 45 yr and older with cardiovascular risk factors undergoing major surgery were enrolled and randomly assigned to receive a preoperative crystalloid bolus within 60 ± 15 min before anesthetic induction, or to receive standard care. The primary outcome was the time-weighted average mean arterial pressure of less than 65 mmHg within the first 20 min after induction or until surgical incision. Results: Of the 504 patients analyzed (247 in the intervention group and 257 in the control group), no statistically significant difference in median time-weighted average of the mean arterial pressure less than 65 mmHg was observed (intervention group, 0.0 mmHg; interquartile range, 0.0 to 0.56; standard of care group, 0.0 mmHg; interquartile range, 0.0 to 0.84; P = 0.368). Conclusions: In this blinded randomized clinical trial, administering a crystalloid fluid bolus within 60 min before surgery did not significantly reduce the time-weighted average of a mean arterial pressure less than 65 mmHg compared to standard care in patients with cardiovascular risk factors undergoing major noncardiac surgery. This study suggests that administering crystalloids before surgery does not prevent postinduction hypotension.


  • Open Access

    Levosimendan and Postoperative Renal Function in Patients with Cardiovascular Risk Factors Undergoing Major Noncardiac Surgery – Secondary Analysis of a Double-Blinded Randomized-Controlled Trial

    by Nicole Hantakova, Christian Reiterer, Barbara Kabon, Alexander Taschner, Nikolas Adamowitsch, Katharina Horvath, Zotti Olliver, Melanie Fraunschiel, Theresa Clement, Edith Fleischmann, et al.

    Background: Acute kidney injury (AKI) is a common and serious complication after noncardiac surgery. While levosimendan has shown renal protective effects in cardiac surgery patients, its impact in non-cardiac surgery – especially among patients with cardiovascular risk factors – remains unknown. Therefore, in this secondary analysis, we evaluated the effect of perioperative levosimendan administration on the incidence of postoperative AKI. We further assessed its impact on perioperative maximum creatinine concentration, estimated glomerular filtration rate (eGFR), and perioperative body composition parameters.Methods: We included all 228 patients from the main trial. Among these, 115 patients were assigned to receive a single dose of levosimendan, while113 patients were allocated to the placebo group. Blood samples and body composition parameters were assessed preoperatively, within one hour after surgery, and on the first, second, third and fifth postoperative day.Results: The incidence of postoperative AKI (p=0.485) did not differ significantly; also, the logistic regression model showed no significant treatment effect between the groups (OR 1.348, 95% CI 0.466 to 4.086; p=0.584). Maximum creatinine concentrations (effect estimate: 0.04 mg.dL-1, 95% CI -0.07 to 0.15; p=0.481), eGFR (effect estimate -1.01mL.min-1.BSA, 95% CI -6.98 to 4.97; p=0.743), and postoperative overhydration were also similar between the groups.Conclusion: Unlike findings in cardiac surgery patients, perioperative levosimendan administration did not provide renal protection in high-risk cardiovascular patients undergoing major noncardiac surgery.

  • Open Access

    Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial

    by Christian Reiterer, Barbara Kabon, Alexander Taschner, Alexandra Graf, Nikolas Adamowitsch, Katharina Horvath, David Emler, Oliver Zotti, Nicole Hantakova, Beatrix Hochreiter, et al.

    The effect of Levosimendan on postoperative natriuretic peptides in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative N-terminal brain pro natriuretic peptide (NT-proBNP) concentrations. In this prospective, double-blinded, parallel group, placebo-controlled, phase III trial 115 patients were assigned to perioperative single-dose of 12.5 mg of levosimendan and 115 to placebo between October 2020 through November 2023 (clinicaltrials.gov: NCT04329624). The primary outcome was postoperative maximum NT-proBNP concentration within the first 3 postoperative days. 228 patients completed the trial. Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: −64.51 ng.L-1; 95% CI −332.66 to 195.56; p = 0.61). Here, we show that perioperative levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP after noncardiac surgery.


  • Open Access

    Levosimendan and postoperative NT-proBNP release in noncardiac surgery – a prospective, randomized, double-blinded, phase III trial

    by Barbara Kabon, Christian Reiterer, Alexander Taschner, Alexandra Graf, Nikolas Adamowitsch, Katharina Horvath, David Emler, Oliver Zotti, Nicole Hantakova, Beatrix Hochreiter, et al.

    Background: Postoperative elevated NT-proBNP concentrations are independently associated with cardiovascular complications and mortality after noncardiac surgery. Levosimendan significantly decreases the release of NT-proBNP, however, the effect in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative maximum NT-proBNP. Methods: 230 cardiovascular risk patients undergoing moderate- to high-risk major noncardiac surgery were included in this prospective, double-blinded, parallel group, placebo-controlled, phase III trial, between October 2020 through November 2023. 115 patients were assigned to perioperative single-dose of 12.5mg starting with a rate of 0.2 mcg.kg-1.min-1 of levosimendan and 115 patients were assigned to placebo. The primary outcome was postoperative maximum NT-proBNP concentration within the first three postoperative days. Secondary outcomes were MINS and maximum troponin T concentrations within the first three postoperative days. Results: Among 230 patients, 228 patients completed the trial. There was no significant difference in postoperative maximum NT-proBNP concentrations between the groups (effect estimate: -82.99ng.L-1; 95% CI -321.08 to 190.96; p=0.48). The incidence of MINS (p=0.063) and postoperative maximum troponin T (effect estimate: 0.45, 95% CI-1.66 to 3.41; p=0.728) concentrations within the first three postoperative days did not differ significantly between the groups. Conclusions: Levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP in cardiovascular risk patients undergoing major noncardiac surgery. There was no significant difference in MINS and postoperative Troponin T concentrations. The role of pre-emptive levosimendan as prophylactic treatment option in cardiovascular high-risk patients must be verified in large-scale trials.

  • Open Access

    Effect of desflurane, sevoflurane or propofol on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major non-cardiac surgery: study protocol for a prospective, randomised, observer-blinded, clinical trial (RAPID-II trial)

    by Alexander Taschner, Edith Fleischmann, Barbara Kabon, Barbara Sinner, Christine Eckhardt, Katharina Horvath, Nikolas Adamowitsch, Nicole Hantakova, Beatrix Hochreiter, Oliver Zotti, et al.

    Introduction: The effect of different anaesthetics on the incidence of postoperative delirium is still not entirely clear. Therefore, we will evaluate the effect of desflurane versus sevoflurane versus propofol for the maintenance of anaesthesia on the incidence of postoperative delirium in older adults undergoing moderate- to high-risk major non-cardiac surgery. We will further compare the incidences of delayed neurocognitive recovery, long-term postoperative neurocognitive disorder, postoperative nausea and vomiting between the groups. Methods and analysis: In this multicentre, prospective, observer-blinded, randomised controlled clinical trial, we will include 1332 patients ≥65 years of age undergoing moderate- to high-risk major non-cardiac surgery lasting at least 2 hours. Patients will be randomly 1:1:1 assigned to receive desflurane, sevoflurane or propofol for anaesthesia. Maintenance of anaesthesia will be performed in a goal-directed manner using processed electroencephalography with an intraoperative goal of bispectral index 40–60. Our primary outcome will be the incidence of postoperative delirium within the first five postoperative days. Postoperative delirium will be assessed using the three-dimensional-confusion assessment method (3D-CAM) or CAM-intensive care unit (ICU) in the morning and evening of the first five postoperative days by blinded study personnel. The primary outcome, the incidence of postoperative delirium, will be compared between the three study groups using a χ 2 test. Furthermore, a logistic regression model for the incidence of postoperative delirium will be performed, accounting for randomised groups as well as other predefined confounding factors. Ethics and dissemination: This clinical trial has been approved by the ethics committee and the Federal Office for Safety in Healthcare as the competent authority for clinical trials in Austria. The results of this trial will be published in a peer-reviewed journal. Trial registration number: ClinicalTrials.gov NCT05990790 .


  • Open Access

    Desflurane Versus Sevoflurane and Postoperative Cardiac Biomarkers in Older Adults Undergoing Low- to Moderate-Risk Noncardiac Surgery—Secondary Analysis of a Prospective, Observer-Blinded, Randomized Clinical Trial

    by Alexander Taschner, Christian Reiterer, Edith Fleischmann, Barbara Kabon, Katharina Horvath, Nikolas Adamowitsch, David Emler, Thomas Christian, Nicole Hantakova, Beatrix Hochreiter, et al.

    Background/Objectives: Previous preclinical studies have shown that desflurane might have the most significant cardioprotective effect of all volatile anesthetics. However, data regarding the cardioprotective effects of desflurane versus sevoflurane are lacking. Therefore, we evaluated the effect of the maintenance of anesthesia using desflurane versus sevoflurane on the postoperative maximum concentrations of cardiac biomarkers in older adults undergoing low- to moderate-risk noncardiac surgery. Methods: In this secondary analysis of a prospective randomized trial, we included all 190 older adults undergoing low- to moderate-risk noncardiac surgery. Patients were randomized to receive desflurane or sevoflurane for the maintenance of anesthesia. We administered desflurane or sevoflurane, aiming at a BIS value of 50 ± 5. The cardiac-specific biomarkers included troponin T, NT-proBNP, and copeptin, which were measured preoperatively, within one hour after surgery, and on the second postoperative day. Results: There were no significant differences between the desflurane and sevoflurane groups in the postoperative maximum concentrations of troponin T (11 ng.L−1 [8; 16] versus 13 ng.L−1 [9; 18]; p = 0.595), NT-proBNP (196 pg.mL−1 [90; 686] versus 253 pg.mL−1 [134; 499]; p = 0.288), or copeptin (19 pmol.L−1 [7; 58] versus 12 pmol.L−1 [6; 41]; p = 0.096). We also observed no significant differences in the troponin T, NT-proBNP, or copeptin concentrations between the desflurane and sevoflurane groups at any measured timepoint (all p > 0.05). Conclusions: In contrast to preclinical studies, we did not observe a significant difference in the postoperative maximum concentrations of cardiac biomarkers. It seems likely that desflurane does not exert significant clinical meaningful cardioprotective effects in older adults. Thus, our results do not support the use of desflurane in patients undergoing low- to moderate-risk noncardiac surgery.


  • Open Access

    Effect of Supplemental Oxygen on von Willebrand Factor Activity and Ristocetin Cofactor Activity in Patients at Risk for Cardiovascular Complications Undergoing Moderate-to High-Risk Major Noncardiac Surgery—A Secondary Analysis of a Randomized Trial

    by Katharina Horvath, Alexander Taschner, Nikolas Adamowitsch, Markus Falkner von Sonnenburg, Edith Fleischmann, Barbara Kabon, Melanie Fraunschiel, Christian Reiterer, Alexandra Graf

    Increased von Willebrand Factor (vWF) activity mediates platelet adhesion and might be a contributor to the development of thrombotic complications after surgery. Although in vitro studies have shown that hyperoxia induces endovascular damage, the effect of perioperative supplemental oxygen as a possible trigger for increased vWF activity has not been investigated yet. We tested our primary hypothesis that the perioperative administration of 80% oxygen concentration increases postoperative vWF activity as compared to 30% oxygen concentration in patients at risk of cardiovascular complications undergoing major noncardiac surgery. A total of 260 patients were randomly assigned to receive 80% versus 30% oxygen throughout surgery and for two hours postoperatively. We assessed vWF activity and Ristocetin cofactor activity in all patients shortly before the induction of anesthesia, within two hours after surgery and on the first and third postoperative day. Patient characteristics were similar in both groups. We found no significant difference in vWF activity in the overall perioperative time course between both randomization groups. We observed significantly increased vWF activity in the overall study population throughout the postoperative time course. Perioperative supplemental oxygen showed no significant effect on postoperative vWF and Ristocetin cofactor activity in cardiac risk patients undergoing major noncardiac surgery. In conclusion, we found no significant influence of supplemental oxygen in patients undergoing major non-cardiac surgery on postoperative vWF activity and Ristocetin cofactor activity.


  • Open Access

    Perioperative Supplemental Oxygen and Postoperative Copeptin Concentrations in Cardiac-Risk Patients Undergoing Major Abdominal Surgery—A Secondary Analysis of a Randomized Clinical Trial

    by Alexander Taschner, Barbara Kabon, Alexandra Graf, Nikolas Adamowitsch, Markus Falkner von Sonnenburg, Melanie Fraunschiel, Katharina Horvath, Edith Fleischmann, Christian Reiterer

    Noncardiac surgery is associated with hemodynamic perturbations, fluid shifts and hypoxic events, causing stress responses. Copeptin is used to assess endogenous stress and predict myocardial injury. Myocardial injury is common after noncardiac surgery, and is often caused by myocardial oxygen demand-and-supply mismatch. In this secondary analysis, we included 173 patients at risk for cardiovascular complications undergoing moderate- to high-risk major abdominal surgery. Patients were randomly assigned to receive 80% or 30% oxygen throughout surgery and the first two postoperative hours. We evaluated the effect of supplemental oxygen on postoperative Copeptin concentrations. Copeptin concentrations were measured preoperatively, within two hours after surgery, on the first and third postoperative days. In total, 85 patients received 0.8 FiO2, and 88 patients received 0.3 FiO2. There was no significant difference in postoperative Copeptin concentrations between both study groups (p = 0.446). Copeptin increased significantly within two hours after surgery, compared with baseline in the overall study population (estimated effect: −241.7 pmol·L−1; 95% CI −264.4, −219.1; p < 0.001). Supplemental oxygen did not significantly attenuate postoperative Copeptin release. Copeptin concentrations showed a more immediate postoperative increase compared with previously established biomarkers. Nevertheless, Copeptin concentrations did not surpass Troponin T in early determination of patients at risk for developing myocardial injury after noncardiac surgery.


  • Open Access

    Perioperative Supplemental Oxygen and Plasma Catecholamine Concentrations after Major Abdominal Surgery—Secondary Analysis of a Randomized Clinical Trial

    by Alexander Taschner, Barbara Kabon, Markus Falkner von Sonnenburg, Alexandra Graf, Nikolas Adamowitsch, Melanie Fraunschiel, Edith Fleischmann, Christian Reiterer

    Perioperative stress is associated with increased sympathetic activity that leads to increases in heart rate and blood pressure, which are associated with the development of perioperative myocardial ischemia. In healthy volunteers, it was shown that the administration of supplemental oxygen attenuated sympathetic nerve activity and subsequently led to lower plasma catecholamine concentrations. We therefore tested the hypothesis that perioperative supplemental oxygen attenuates sympathetic nerve in patients at risk for cardiovascular complications undergoing major abdominal surgery. We randomly assigned 81 patients to receive either 80% or 30% inspired oxygen concentration throughout surgery and the first two postoperative hours. We assessed noradrenaline, adrenaline, and dopamine plasma concentrations before the induction of anesthesia, two hours after surgery and on the third postoperative day. There was no significant difference in postoperative noradrenaline (effect estimated: −41.5 ng·L−1, 95%CI −134.3, 51.2; p = 0.38), adrenaline (effect estimated: 11.2 ng·L−1, 95%CI −7.6, 30.1; p = 0.24), and dopamine (effect estimated: −1.61 ng·L−1, 95%CI −7.2, 3.9; p = 0.57) concentrations between both groups. Based on our results, it seems unlikely that supplemental oxygen influences endogenous catecholamine release in the perioperative setting.